Corticosteroids induce expression of transforming-growth-factor-betal mRNA in peripheral blood mononuclear cells of patients with multiple sclerosis

Journal of Neuroimmunology

Volumn 84, Issue 1, 1998, Pages 1-6

  Ossege, L M ^a   Sindern, E ^a   Voss, B ^b   Malin, J P ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b Prof Associations' Res Inst O   (Germany)

Author keywords

Corticosteroids; Cytokines; Immunomodulation; Multiple sclerosis; Termination of inflammatory reaction; Transforming growth factor betal

Indexed keywords

MESSENGER RNA; PREDNISOLONE; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DRUG EFFICACY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MULTIPLE SCLEROSIS; PREDNISOLONE; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA;

EID: 0032054102     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(97)00211-7     Document Type: Article

References (38)

1. AnylarBatuman O., Ferrero A.P., Diaz A., Jimenez S.A. Regulation of transforming growth factor-β1 gene expression by glucocorticoids in normal human T-lymphocytes. J. Clin. Invest. 88:1991;1574-1580.
2. Arya S.K., Wong-Staal F., Gallo R.C. Dexamethasone-mediated inhibition of human T-cells growth factor and γ-interferon messenger RNA. J. Immunol. 133:1994;273-276.
3. Beck J., Rondot P., Catinot L., Falcoff E., Kirchner H., Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: Do cytokines trigger off exacerbations? Acta Neurol. Scand. 78:1988;318-323.
4. Chicanza I.C., Panayi G.S. The effects of hydrocortisone on in vitro lymphocyte proliferation and interleukin-2- and -4 production in corticosteroid sensitive and resistant subjects. Eur. J. Clin. Invest. 23:1993;845-850.
5. Denhardt D.T. A membrane filter technique for detection of complementary DNA. Biochem. Biophys. Res. Commun. 23:1966;641-646.
6. Durelli L., Cocito D., Riccio A., Barile C., Bergamasco B., Baggio G.F., Perla F., Delsedime M., Gusmaroli G., Bergamini L. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: Clinical-immunological correlations. Neurology. 36:1986;238-243.
7. Feinberg A.P., Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem. 132:1983;6-13.
8. Gall J.C., Pardue M.L. Formation and detection of RNA-DNA hybrid molecules in cytological preparations. Proc. Natl. Acad. Sci. USA. 63:1969;378-383.
9. Gillis S., Crabtree G.R., Smith K.A. Glucocorticoid-induced inhibition of T-cell growth factor production. I. The effect on mitogen-induced lymphocyte proliferation. J. Immunol. 123:1979;1624-1631.
10. Grotendorst G.R., Smale G., Penev D. Production of transforming growth factor beta by human peripheral blood monocytes and neutrophils. Cell. Physiol. 140:1989;396-402.
11. Kehrl J.H., Wakefield L.M., Roberts A.B., Jakowlew S., Alvarez-Mon M., Dernyck R., Sporn M.B., Fauci A.S. Production of transforming growth factor beta by human T-lymphocytes and its potential role in the regulation of T-cell growth. J. Exp. Med. 163:1988;1037-1050.
12. Kekow J., Gross W.L. Transforming growth factor beta: Wirkungsweise und klinische Bedeutung. Dtsch. Med. Wochenschr. 117:1992;228-235.
13. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology. 33:1983;1444-1452.
14. Lawrence D.A., Pircher R., Jullien P. Conversion of a high molecular weight latent beta-TGF from chicken embryo fibroblasts into a low molecular weight active beta-TGF under acidic conditions. Biochem. Biophys. Res. Commun. 133:1985;1026-1034.
15. Link J., Söderström M., Olson T., Höjeberg B., Ljungdahl Å., Link H. Increased transforming growth factor-β, interleukin-4 and interferon-γ in multiple sclerosis. Ann. Neurol. 36:1994;379-386.
16. Lo W. Localization of low abundance DNA sequences in tissue section by in situ hybridization. J. Cell. Sci. 81:1986;143-162.
17. Lyons P.R., Newman P.K., Saunders M. Methylprednisolone therapy in multiple sclerosis: A profile of adverse effects. J. Neurol. Neurosurg. Psychiatry. 51:1988;285-287.
18. Martin R., McFarland H.F., McFarlin D.E. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 10:1992;153-187.
19. McFarlin D.E., McFarland H.F. Multiple sclerosis. N. Engl. J. Med. 307:1982;1183-1188.
20. Navikas V., Link J., Palasik W., Söderström M., Fredrikson S., Olsson T., Link H. Increased mRNA expression of Il-10 in mononuclear cells in multiple sclerosis and optic neuritis. Scand. J. Immunol. 41:1995;171-178.
21. Ogden, R.C., Adams, D., 1987. Electrophoresis in agarose und acrylamide gels. In: Berger, S.L., Kimmel, A.R. (Eds.), Guide to Molecular Cloning Technique. Methods in Enzymology, vol 152. Orlando and London, Academic Press, pp. 61-87.
22. Ossege L.M., Voss B., Wiethege T., Sindern E., Malin J.P. Detection of transforming growth factor beta1 mRNA in cerebrospinal fluid cells in patients with meningitis by non-radioactive in situ hybridization. J. Neurol. 242:1994;14-19.
23. Panitch H.S., Hirsch R.L., Schindler J., Johnson K.P. Treatment of multiple sclerosis with gamma interferon: Exacerbations associated with activation of the immune system. Neurology. 37:1987;1097-1102.
24. Pohle T., Shahin M., Gillessen A., Schuppan D., Herbst H., Domschke W. Expression of type I and IV collagen mRNAs in healing gastric ulcers: A comparative analysis using isotopic and non-radioactive in situ hybridization. Histochem. Cell. Biol. 106:1996;413-418.
25. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley A.W., Silberberg D.H., Tourtellotte W.W. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann. Neurol. 13:1983;227-231.
26. Pountain G.D., Keogan M.T., Hazleman B.L., Brown D.L. Effects of single dose compared with three days' prednisolone treatment of healthy volunteers: contrasting effects on circulating lymphocyte subsets. J. Clin. Pathol. 46:1993;1089-1092.
27. Ranges G.E., Fiagri I.S., Espevic T., Paladino M.A. Jr. Inhibition of cytotoxic T-cell development by transforming growth factor beta and reversal by tumor necrosis factor alpha. J. Exp. Med. 166:1987;991-998.
28. Rieckmann P., Albrecht B.A., Kitze B., Weber T., Tumsni H., Broocks A., Lüer W., Helwig A., Poser S. Tumor necrosis factor-α messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann. Neurol. 37:1995;82-88.
29. Rook A.H., Kehrl J.H., Wakefield L.M., Roberts A.B., Sporn M.B., Burlington D.B. Effects of transforming growth factor beta on the functions of natural killer cells: Depressed cytolytic activity and blunting of interferon responsiveness. J. Immunol. 136:1986;3916-3920.
30. Rudick R.A., Ransohoff R.M. Cytokine secretion by multiple sclerosis monocytes. Relationship to disease activity. Arch. Neurol. 49:1992;265-270.
31. Sasaki H., Pollard R.B., Schmitt D., Suzuki F. Transforming growth factor-β in the regulation of the immune response. Clin. Immunol. Immunopathol. 65:1989;1.
32. Schule R., Muller R.M., Kaltschmidt C., Renkawitz R. Many transcription factors interact synergistically with steroid receptors. Science. 242:1988;1418-1420.
33. Shalaby M.R., Ammann A.J. Suppression of immune cell function in vitro by recombinant human transforming-growth-factor-beta. Cell. Immunol. 112:1988;343-350.
34. Sharief M.K., Hentges R. Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. N. Engl. J. Med. 325:1991;467-472.
35. Sporn M.B., Roberts A.B., Wakefield L.M., DeCombrugghe B. Some recent advances in the chemistry and biology of transforming growth factor beta. J. Cell. Biol. 195:1987;1039-1045.
36. Sugarman B.J., Lewis G.D., Essalu T.E., Aggarwal B.B., Shepard H.M. Effects of growth factors on the antiproliferative activity of tumor necrosis factors. Cancer Res. 37:1987;780-786.
37. Troiano R., Cook S.D., Dowling P.C. Steroid therapy in multiple sclerosis. Point of view. Arch. Neurol. 44:1987;803-807.
38. Warren K.G., Catz I., Carroll D.J. Effects of high-two-mega-dose synthetic corticosteroids on multiple sclerosis patients with special reference to cerebrospinal fluid antibodies to myelin basic protein. Clin. Neuropharmacol. 10:1987;397-411.